With the implementation of several FDA‐approved HER2‐targted therapies, breast cancer was one of the earliest cancers where implementing targeted therapies have shown a prolonged survival in patients whose tumors are driven by this tyrosine kinase activation 7. The gene discussed is ERBB2; the disease is breast carcinoma.